No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NTLA Intellia Therapeutics
- 25.790
- +1.160+4.71%
Close Jul 12 16:00 ET
- 26.090
- +0.300+1.16%
Post 19:41 ET
2.49BMarket Cap-4802P/E (TTM)
26.820High24.990Low1.98MVolume25.030Open24.630Pre Close51.46MTurnover2.08%Turnover RatioLossP/E (Static)96.48MShares46.00052wk High2.40P/B2.46BFloat Cap19.37052wk Low--Dividend TTM95.31MShs Float202.730Historical High--Div YieldTTM7.43%Amplitude9.180Historical Low25.927Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday.Shares of The Bank of New York Mellon Corporation (NYSE:BK) rose during Friday's session following better-
All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy
Stifel Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $80
Stifel analyst Dae Gon Ha maintains $Intellia Therapeutics(NTLA.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 37.7% and
Stifel Nicolaus Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
The Past Three Years for Intellia Therapeutics (NASDAQ:NTLA) Investors Has Not Been Profitable
Every investor on earth makes bad calls sometimes. But really big losses can really drag down an overall portfolio. So spare a thought for the long term shareholders of Intellia Therapeutics, Inc. (
Comments
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
7
If you had invested $10,000 in Cathie Wood's $ARK Innovation ETF(ARKK.US$ and Warren Buffett's Berkshire Hathaway $Berkshire Hathaway-B(BRK.B.US$ at different time frames here's how much you'd have today.
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
+3
$Berkshire Hathaway 13F(LIST2999.US$ $Berkshire Hathaway-A(BRK.A.US$ $Berkshire Hathaway-B(BRK.B.US$ $ARK Innovation ETF(ARKK.US$ $Coinbase(COIN.US$ $Apple(AAPL.US$ $Bank of America(BAC.US$ $American Express(AXP.US$ $S&P 500 Index(.SPX.US$ $CRISPR Therapeutics(CRSP.US$ $Intellia Therapeutics(NTLA.US$
2
2
Insiders selling shares at low prices may signal expected stock weakness. The absence of insider buying and increased selling over the past year suggest the shares aren't cheap, making the company a cautious investment.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
